Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche Discontinues PDL Asthma Project | Contract Pharma

What are you searching for?

Sign in
Breaking News

Roche Discontinues PDL Asthma Project

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche has discontinued its involvement with PDL BioPharma in the development of daclizumab in asthma, which the companies had been co-developing since 2004. The decision, following a portfolio review at Roche, has no effect on the companies’ ongoing collaboration to co-develop daclizumab in transplant maintenance, and the companies intend to proceed with planned Phase II studies for the transplant indication during 2007.

As a result, PDL now holds exclusive development and commercial rights to daclizumab in asthma. In a separate collaboration, Biogen Idec and PDL are developing daclizumab in multiple sclerosis and indications other than transplant and respiratory diseases.

“We are evaluating opportunities to establish a new collaboration and would need to partner this program in order to further develop daclizumab in asthma,” said Mark McDade, chief executive officer, PDL BioPharma. “In the meantime, we will redouble our efforts to focus daclizumab development in MS and chronic transplant.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters